An interventional study of Nifedipine and Placebo Ointment Base in Levator Ani Syndrome, sponsored by Vanderbilt University. Withdrawn at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-22.
Sponsored by Vanderbilt University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.
Among the 152 studies in Pelvic Pain with a site in United States, this one is the 117th largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2012, is one of 72 with no phase, and was the 48th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 8–18
Oregon Health and Science University · Sites in United States
Ages 18–45 · Women only
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 50 across the 124 interventional studies, 104 across the 28 observational. Of the 96 that completed or were terminated, 35 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 152 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University is the lead sponsor of 522 studies on the registry; 20 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Vanderbilt University has 1 study filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
16 of the studies in Pelvic Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06110065University of ArizonaCT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain | 2026-11 |
| NCT05354869University of California, Los AngelesTransvaginal Electrical Stimulation for Myofascial Pelvic Pain | 2026-12 |
| NCT03794466University of Kansas Medical CenterQuantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization | 2026-12-31 |
| NCT06083597Weill Medical College of Cornell UniversityDevelopment of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain | 2026-12-31 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 152 studies in Pelvic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to perform a randomized controlled trial among female patients with a diagnosis of pelvic floor hypertonus (extreme muscle tension) with associated pain, dysfunctional voiding, dyspareunia, and/ or obstructed defecation.
Given the paucity of information and the magnitude of debilitation that can be associated with chronic pain syndromes, the potential to ameliorate pain and successfully treat these symptoms is an area that merits further exploration. In this study, we hypothesize that the addition of vaginal nifedipine to a physical therapy protocol will result in greater treatment success than treatment with physical therapy alone.
The objective is to perform a randomized controlled trial among female participants with a diagnosis of pelvic floor hypertonus with associated pain, dysfunctional voiding, dyspareunia, and/or obstructed defecation. Group 1 will serve as the control and will undergo pelvic floor physical therapy and placebo (lanolin and mineral oil base). Group 2 will also undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
Specific aims include:
Group 1 will serve as the control and will undergo pelvic floor physical therapy and placebo (lanolin base). Group 2 will also undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine. We will collect data on these patients to determine if the treatment of vaginal nifedipine with physical therapy provides a more successful treatment for this pelvic floor dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
Drug: Placebo Ointment Base
Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
Drug: Nifedipine
Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Improvement in Quality of Life
The primary outcome will measure quality of life metrics, as reported by the patient herself. We will use the following validated instruments: Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and validated 11-point pain scale. The aim is to measure whether the patient experienced improvement in her symptoms when vaginal nifedipine was administered (in addition to physical therapy).
Time frame: To be assessed 1 month post-treatment.
Improvement in Hypertonic Pelvic Floor Muscles
The secondary outcome measure will be assessed and reported by the healthcare provider at the above visits. After instructing the patient to voluntarily relax the pelvic floor muscles, the resting tone will be measured using the Oxford scale, which is a validated digital assessment.
Time frame: To be assessed at baseline and the following post-treatment intervals: 1, 2, 3, and 6 months
The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nifedipine